LBx Bio

A new cadence for molecular disease monitoring.

Centralized tests happen too rarely to see disease change as it unfolds. LBx Bio is developing a compact platform that monitors molecular signals in the intervals between — surfacing meaningful change earlier and routing it into confirmatory testing through existing clinical workflows.

LBx Bio product image

Beginning in oncology.

Oncology is where the gaps cost the most. Disease trajectory, treatment response, recurrence risk, and follow-up decisions all turn on visibility that centralized testing leaves incomplete.

Earlier signal, clearer action

Built for high-need care settings, where repeatable biomarker insight supports better follow-up and sharper decision windows.

Longitudinal disease visibility

Disease seen over time, not as isolated testing moments.

Clinical monitoring infrastructure

Designed to connect biomarker signal, patient trajectory, and clinical context into a single monitoring layer.

Our partners

University of Waterloo
University of Toronto
H2i / Health Innovation Hub
SPEC Labs
Innovation Boost Zone / IBZ
Intellectual Property Ontario / IPON
Brampton Venture Zone
Innovation Factory